Heterologous regulation of the cannabinoid type 1 receptor by angiotensin II in astrocytes of spontaneously hypertensive rats

Journal of Neurochemistry

Volumn 139, Issue 4, 2016, Pages 523-536

  Haspula, Dhanush ^a   Clark, Michelle A ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

angiotensin II; astroglia; brainstem; cerebellum; hypertension; spontaneously hypertensive rat

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; CANNABINOID 1 RECEPTOR; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HOMEOSTASIS; MALE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION; AGONISTS; ANIMAL; BLOOD PRESSURE; CELL CULTURE; DRUG EFFECTS; FEMALE; HYPERTENSION; METABOLISM; NEWBORN; PHYSIOLOGY; SIGNAL TRANSDUCTION; WISTAR RAT;

ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; BLOOD PRESSURE; CELLS, CULTURED; FEMALE; HYPERTENSION; RATS; RATS, INBRED SHR; RATS, WISTAR; RECEPTOR CROSS-TALK; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, CANNABINOID, CB1;

EID: 84991107631     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13776     Document Type: Article

References (70)

1. Adams H. R., Szilagyi P. G., Gebhardt L. and Lande M. B. (2010) Learning and attention problems among children with pediatric primary hypertension. Pediatrics 126, e1425–e1429.
2. Adriani W., Caprioli A., Granstrem O., Carli M. and Laviola G. (2003) The spontaneously hypertensive-rat as an animal model of ADHD: evidence for impulsive and non-impulsive subpopulations. Neurosci. Biobehav. Rev. 27, 639–651.
3. Agarwal D., Welsch M. A., Keller J. N. and Francis J. (2011) Chronic exercise modulates RAS components and improves balance between pro- and anti-inflammatory cytokines in the brain of SHR. Basic Res. Cardiol. 106, 1069–1085.
4. Bátkai S., Pacher P., Osei-Hyiaman D. et al. (2004) Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110, 1996–2002.
5. Börner C., Höllt V., Sebald W. and Kraus J. (2007) Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. J. Leukoc. Biol. 81, 336–343.
6. Bosier B., Bellocchio L., Metna-Laurent M. et al. (2013) Astroglial CB1 cannabinoid receptors regulate leptin signaling in mouse brain astrocytes. Mol. Metab. 2, 393–404.
7. Castellanos F. X., Giedd J. N., Marsh W. L. et al. (1996) Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch. Gen. Psychiatry 53, 607–616.
8. Chiang Y.-C., Lo Y.-N. and Chen J.-C. (2013) Crosstalk between dopamine D₂ receptors and cannabinoid CB₁ receptors regulates CNR1 promoter activity via ERK1/2 signaling. J. Neurochem. 127, 163–176.
9. Clark M. A., Guillaume G. and Pierre-Louis H. C. (2008) Angiotensin II induces proliferation of cultured rat astrocytes through c-Jun N-terminal kinase. Brain Res. Bull. 75, 101–106.
10. Clark M. A., Nguyen C. and Tran H. (2013) Distinct molecular effects of angiotensin II and angiotensin III in rat astrocytes. Int. J. Hypertens. 2013, 782861.
11. Côté F., Do T. H., Laflamme L., Gallo J. M. and Gallo-Payet N. (1999) Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J. Biol. Chem. 274, 31686–31692.
12. Devane W. A., Dysarz F. A., Johnson M. R., Melvin L. S. and Howlett A. C. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605–613.
13. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A. and Mechoulam R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946–1949.
14. Di Marzo V. (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov. 7, 438–455.
15. Downie L. E., Vessey K., Miller A., Ward M. M., Pianta M. J., Vingrys A. J., Wilkinson-Berka J. L. and Fletcher E. L. (2009) Neuronal and glial cell expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in the rat retina. Neuroscience 161, 195–213.
16. Freund T. F., Katona I. and Piomelli D. (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83, 1017–1066.
17. Goetz M., Schwabova J., Hlavka Z., Ptacek R., Zumrova A., Hort V. and Doyle R. (2014) Cerebellar symptoms are associated with omission errors and variability of response time in children with ADHD. J. Atten. Disord.
18. Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., de Costa B. R. and Rice K. C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563–583.
19. Ibrahim B. M. and Abdel-Rahman A. A. (2011) Role of brainstem GABAergic signaling in central cannabinoid receptor evoked sympathoexcitation and pressor responses in conscious rats. Brain Res. 1414, 1–9.
20. Isegawa K., Hirooka Y., Katsuki M., Kishi T. and Sunagawa K. (2014) Angiotensin II type 1 receptor expression in astrocytes is upregulated leading to increased mortality in mice with myocardial infarction-induced heart failure. Am. J. Physiol. Heart Circ. Physiol. 307, H1448–H1455.
21. Jean-Gilles L., Braitch M., Latif M. L. et al. (2015) Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells. Acta Physiol. (Oxf) 214, 63–74.
22. Kandalam U. and Clark M. A. (2010) Angiotensin II activates JAK2/STAT3 pathway and induces interleukin-6 production in cultured rat brainstem astrocytes. Regul. Pept. 159, 110–116.
23. Lake K. D., Martin B. R., Kunos G. and Varga K. (1997) Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29, 1204–1210.
24. Lanz T. V., Ding Z., Ho P. P. et al. (2010) Angiotensin II sustains brain inflammation in mice via TGF-beta. J. Clin. Invest. 120, 2782–2794.
25. Laprairie R. B., Kelly M. E. M. and Denovan-Wright E. M. (2013) Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease. Neuropharmacology 72, 47–57.
26. Li Y., Xiao D., Dasgupta C., Xiong F., Tong W., Yang S. and Zhang L. (2012) Perinatal nicotine exposure increases vulnerability of hypoxic-ischemic brain injury in neonatal rats: role of angiotensin II receptors. Stroke 43, 2483–2490.
27. Lim G., Sung B., Ji R.-R. and Mao J. (2003) Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105, 275–283.
28. Liu G., Hosomi N., Hitomi H., Pelisch N., Fu H., Masugata H., Murao K., Ueno M., Matsumoto M. and Nishiyama A. (2011) Angiotensin II induces human astrocyte senescence through reactive oxygen species production. Hypertens. Res. 34, 479–483.
29. Livak K. J. and Schmittgen T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408.
30. Maier T., Güell M. and Serrano L. (2009) Correlation of mRNA and protein in complex biological samples. FEBS Lett. 583, 3966–3973.
31. Manzanares J., Julian M. and Carrascosa A. (2006) Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr. Neuropharmacol. 4, 239–257.
32. Massi P., Valenti M., Bolognini D. and Parolaro D. (2008) Expression and function of the endocannabinoid system in glial cells. Curr. Pharm. Des. 14, 2289–2298.
33. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C. and Bonner T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561–564.
34. Miller L. K. and Devi L. A. (2011) The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol. Rev. 63, 461–470.
35. Mogi M. and Horiuchi M. (2009) Effects of angiotensin II receptor blockers on dementia. Hypertens. Res. 32, 738–740.
36. Molina-Holgado F., Molina-Holgado E., Guaza C. and Rothwell N. J. (2002) Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J. Neurosci. Res. 67, 829–836.
37. Molina-Holgado F., Pinteaux E., Moore J. D., Molina-Holgado E., Guaza C., Gibson R. M. and Rothwell N. J. (2003) Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 23, 6470–6474.
38. Munro S., Thomas K. L. and Abu-Shaar M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61–65.
39. Nade V. S., Kawale L. A., Valte K. D. and Shendye N. V. (2015) Cognitive enhancing effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on learning and memory. Indian J. Pharmacol. 47, 263–269.
40. Navarrete M. and Araque A. (2008) Endocannabinoids mediate neuron-astrocyte communication. Neuron 57, 883–893.
41. Pacher P., Bátkai S. and Kunos G. (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58, 389–462.
42. Park M.-H., Kim H. N., Lim J. S., Ahn J.-S. and Koh J.-Y. (2013) Angiotensin II potentiates zinc-induced cortical neuronal death by acting on angiotensin II type 2 receptor. Mol. Brain 6, 50.
43. Parmentier-Batteur S., Jin K., Mao X. O., Xie L. and Greenberg D. A. (2002) Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J. Neurosci. 22, 9771–9775.
44. Patel S. and Hillard C. J. (2001) Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. J. Pharmacol. Exp. Ther. 297, 629–637.
45. Qian Y., Lei G., Castellanos F. X., Forssberg H. and Heijtz R. D. (2010) Deficits in fine motor skills in a genetic animal model of ADHD. Behav. Brain Funct. 6, 51.
46. Reja V., Goodchild A. K., Phillips J. K. and Pilowsky P. M. (2006) Upregulation of angiotensin AT1 receptor and intracellular kinase gene expression in hypertensive rats. Clin. Exp. Pharmacol. Physiol. 33, 690–695.
47. Rozenfeld R., Gupta A., Gagnidze K., Lim M. P., Gomes I., Lee-Ramos D., Nieto N. and Devi L. A. (2011) AT1R-CB₁R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J. 30, 2350–2363.
48. Schaich C. L., Shaltout H. A., Brosnihan K. B., Howlett A. C. and Diz D. I. (2014) Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats. Physiol. Rep. 2, e12108. DOI: 10.14814/phy2.12108.
49. Seagard J. L., Dean C., Patel S., Rademacher D. J., Hopp F. A., Schmeling W. T. and Hillard C. J. (2004) Anandamide content and interaction of endocannabinoid/GABA modulatory effects in the NTS on baroreflex-evoked sympathoinhibition. Am. J. Physiol. Heart Circ. Physiol. 286, H992–H1000.
50. Seyedabadi M., Goodchild A. K. and Pilowsky P. M. (2001) Differential Role of Kinases in Brain Stem of Hypertensive and Normotensive Rats. Hypertension 38, 1087–1092.
51. Sheng W. S., Hu S., Min X., Cabral G. A., Lokensgard J. R. and Peterson P. K. (2005) Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211–219.
52. Shi P., Raizada M. K. and Sumners C. (2010) Brain cytokines as neuromodulators in cardiovascular control. Clin. Exp. Pharmacol. Physiol. 37, e52–e57.
53. Song C. and Howlett A. C. (1995) Rat brain cannabinoid receptors are N-linked glycosylated proteins. Life Sci. 56, 1983–1989.
54. Steckelings U. M., Larhed M., Hallberg A., Widdop R. E., Jones E. S., Wallinder C., Namsolleck P., Dahlöf B. and Unger T. (2011) Non-peptide AT2-receptor agonists. Curr. Opin. Pharmacol. 11, 187–192.
55. Stella N. (2004) Cannabinoid signaling in glial cells. Glia 48, 267–277.
56. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A. and Waku K. (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89–97.
57. Szekeres M., Nádasy G. L., Turu G., Soltész-Katona E., Tóth Z. E., Balla A., Catt K. J. and Hunyady L. (2012) Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors. J. Biol. Chem. 287, 31540–31550.
58. Tallant E. A. and Higson J. T. (1997) Angiotensin II activates distinct signal transduction pathways in astrocytes isolated from neonatal rat brain. Glia 19, 333–342.
59. Teixeira-Clerc F., Julien B., Grenard P., Tran Van Nhieu J., Deveaux V., Li L., Serriere-Lanneau V., Ledent C., Mallat A. and Lotersztajn S. (2006) CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 12, 671–676.
60. Tham D. M., Martin-McNulty B., Wang Y., Wilson D. W., Vergona R., Sullivan M. E., Dole W. and Rutledge J. C. (2002) Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol. Genomics 11, 21–30.
61. Tiyerili V., Zimmer S., Jung S., Wassmann K., Naehle C. P., Lütjohann D., Zimmer A., Nickenig G. and Wassmann S. (2010) CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res. Cardiol. 105, 465–477.
62. Tsou K., Brown S., Sañudo-Peña M. C., Mackie K. and Walker J. M. (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393–411.
63. Turu G., Várnai P., Gyombolai P., Szidonya L., Offertaler L., Bagdy G., Kunos G. and Hunyady L. (2009) Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other Gq/11 protein-coupled receptors. J. Biol. Chem. 284, 16914–16921.
64. Van Sickle M. D., Oland L. D., Ho W., Hillard C. J., Mackie K., Davison J. S. and Sharkey K. A. (2001) Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121, 767–774.
65. Veerasingham S. J. and Raizada M. K. (2003) Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives. Br. J. Pharmacol. 139, 191–202.
66. Waki H., Gouraud S. S., Maeda M. and Paton J. F. R. (2008) Specific inflammatory condition in nucleus tractus solitarii of the SHR: novel insight for neurogenic hypertension? Auton. Neurosci. 142, 25–31.
67. Walter L., Franklin A., Witting A., Moller T. and Stella N. (2002) Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem. 277, 20869–20876.
68. Winklewski P. J., Radkowski M., Wszedybyl-Winklewska M. and Demkow U. (2015) Brain inflammation and hypertension: the chicken or the egg? J. Neuroinflammation 12, 85.
69. Wolozin B., Lee A., Lee A., Whitmer R. and Kazis L. (2008) O1-05-05: use of angiotensin receptor blockers is associated with a lower incidence and progression of Alzheimer's disease. Alzheimers Dement. 4, T118.
70. Yun H.-S., Park M.-S., Ji E.-S., Kim T.-W., Ko I.-G., Kim H.-B. and Kim H. (2014) Treadmill exercise ameliorates symptoms of attention deficit/hyperactivity disorder through reducing Purkinje cell loss and astrocytic reaction in spontaneous hypertensive rats. J. Exerc. Rehabil. 10, 22–30.